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AIM OF THIS STUDY 
1.To find out the Prevalence and General Characteristics of  Non Alcoholic 
Fatty Liver Disease in persons with Type 2 Diabetes Mellitus attending 
outpatient clinic in Thanjavur Medical College.  
 
2.To asses the different clinical presentations of Non Alcoholic Fatty Liver 
Disease in Type 2 Diabetes Mellitus Patients. 
 
3.To asses the relationship between Body Mass Index and Non Alcoholic 
Fatty Liver Disease in Type 2 Diabetes Mellitus.  
 
4. To correlate the results of Liver Function Tests with Ultrasonographic 
evidence of fatty liver in Type 2 Diabetes Mellitus. 
 
5. To correlate the results of fasting Lipid Profile with Ultrasonographic 
evidence of fatty liver in Type 2 Diabetes Mellitus. 
 
 
  
                              INTRODUCTION 
 
Diabetes mellitus is a common metabolic disorder that affects a large 
number of people worldwide, the diabetic population is ever growing and it 
has now reached enormous proportions. Diabetes mellitus affects almost all  
systems in the body and it causes considerable morbidity and mortality. 
The liver is the hub of most of the metabolic activities and it plays a vital 
role in the metabolism of carbohydrates, proteins and lipids. Affection of 
liver in diabetes has been studied by many investigators. Of particular 
interest is an entity called Non alcoholic fatty liver disease (NAFLD) which 
occurs in a significant proportion of people who do not consume alcohol. 
Diabetes Mellitus, Hyperlipidemia and Obesity have been implicated as 
potential causes for the development of non alcoholic fatty liver disease and 
now newer risk factors have also been proposed. Nonalcoholic Fatty Liver 
Disease is a broader term that encompasses a spectrum including patients 
with simple steatosis, steatohepatitis that can progress to cirrhosis liver and 
even hepatocellular carcinoma. A plethora of case series of Non Alcoholic 
Fatty Liver Disease have been reported over the past few years but whether 
this indicates a true increase in prevalence or simply an increased awareness 
of this disorder is unclear.  There have been a lot of studies done on Non 
Alcoholic Fatty Liver Disease in many centers around the world and a few 
centers in India. No such study has been conducted till date in this part of our 
country. 
Thanjavur Medical College located in Tamilnadu caters to the medical 
needs of a large diabetic population of about 3 districts; many cases of 
diabetes mellitus also have chronic liver disease, some of them do not have a 
history of significant alcohol consumption, so we thought that these cases 
might represent a sample of what is called cryptogenic cirrhosis. 
A significant proportion of patients previously thought to have 
cryptogenic cirrhosis share many of the clinical and demographic features of 
nonalcoholic fatty liver disease, suggesting that the etiology of their cirrhosis 
may be unrecognized nonalcoholic fatty liver disease.   
So we conducted this study to evaluate the prevalence and general 
characteristics of Nonalcoholic Fatty Liver Disease in type 2 diabetics with a 
motive to provide some information that might be useful for future reference 
and to evaluate the impact of this disease on persons belonging to this 
geographical region. 
 1
MATERIALS AND METHODS 
 
Inclusion criteria 
Patients who were diagnosed to have Type 2 Diabetes Mellitus, for more 
than 3 years duration, belonging to both sexes and with age of more than 40 
years attending Diabetology Out - Patient Department of Thanjavur Medical 
College were included in the study. 
 
 
Exclusion criteria 
Patients with history of alcohol consumption for any duration of time were 
excluded. 
Persons with previous history of Jaundice, Ascites, and signs of Liver cell 
failure were excluded. 
Persons who tested positive for Hepatitis B serology by Elisa or by card test 
were excluded. 
Patients with history of intake of Drugs, Methotrexate, Amiodarone, 
Glucocorticoids, Synthetic Estrogens, Glitazones, Nucleoside Analogues 
(ddI, AZT) were excluded. 
Persons with history of  major abdominal surgeries were excluded. 
 2
Persons with history of Chronic Renal Failure and Severe Ischemic Heart 
Disease were excluded from the study. 
Patients with a history of Ketoacidosis or with a history prolonged treatment 
with insulin were excluded. 
 
 
The Study Population was derived from the patients attending the 
Diabetology Outpatient Department of Thanjavur Medical College from 
April 2004 to January 2006. 
A detailed history was taken regarding the Duration of Diabetes, Symptoms 
pertaining to the Hepatobiliary System  
History of medications was obtained in detail. 
History of alcohol consumption was recorded and any person with history of 
alcohol use was excluded from the study population. 
Any history of previous abdominal surgeries such as Jejuno Ileal Bypass, 
Gastrectomy was recorded. 
Women were enquired about oral contraceptive or hormonal use. 
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A detailed Clinical Examination of all systems was made and signs of Liver 
Cell Failure, Organomegaly, Ascites were looked for. 
The patient’s Height & Weight were recorded & Body Mass Index was 
calculated. 
 BMI was defined as weight in kilograms divided by (height in meters) 2. 
Patients were classified according to BMI as follows: 
Underweight: BMI < 18.5 kg/m2 
Normal weight: BMI 18.5 to 24.9 kg/m2 
Overweight: BMI 25 to 29.9 kg/m2 
Obese: BMI > 30 kg/m2 
Blood Pressure measurements were taken. 
THE LABORATORY INVESTIGATIONS DONE INCLUDED: 
A Complete Blood Count. 
Urine for Albumin Sugar and Deposits. 
Blood Sugar (Random, Fasting & Post Prandial). 
Blood Urea and Serum Creatinine. 
Serum Electrolytes (Sodium & Potassium). 
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LIVER FUNCTION TESTS 
    SGOT (Normal value 5 to 35 IU/L) 
    SGPT (Normal value 5 to 35 IU/L) 
    Serum Alkaline Phospatase (Normal value 60 to 170 IU/L) 
    Serum Total Bilurubin (Normal value < 1 mg/dl) 
    Serum Total Proteins  
FASTING LIPID PROFILE 
The fasting lipid profile was done after a minimum of 12 hours of overnight 
fasting and the following tests were done 
Serum Total Cholesterol 
Serum Triglycerides (TGL) 
Serum High Density Lipoprotein (HDL) 
Serum Low Density Lipoprotein (LDL) was calculated using the Friedwald 
formula: 
LDL-C = Total Cholesterol - HDL C – (Triglyceride/ 5). 
 
All the Biochemical Investigations were done using Auto-analyzer technique 
with the ERBA XL 300 AUTOANALYZER. 
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Ultrasonogram of Abdomen was done with particular focus on the liver. 
Liver biopsy was done in a few selected cases considering the invasive 
nature of this procedure if necessary with a fully informed and detailed 
consent. 
 
The presence of diabetes was defined according to the WHO CRITERIA99 
as: 
Symptoms of diabetes, plus Random Blood Glucose concentration 
more than 200 mg/dl. 
Fasting plasma glucose more than 126 mg/dl. (Fasting is defined as 
No caloric intake for at least 8h) 
Two hour plasma glucose more than 200 mg/dl during an oral 
Glucose tolerance test. (This test should be done using a glucose load 
containing the equivalent of 75 g anhydrous glucose dissolved in water) 
 
Type 2 DM subjects were defined as those with previous physician-
diagnosed diabetes in whom hyperglycemia had been controlled for one year 
or more with oral hypoglycemic agents and diet, with absence of history of 
ketoacidosis initially, or during the course of the disease 103,104. 
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IMAGING STUDY: 
An Ultrasound scan of the abdomen was done with particular focus on the 
liver 
Steatosis was defined as the presence of an ultrasonographic pattern 
consistent with "BRIGHT LIVER," with evident ultrasonographic contrast 
between hepatic and renal parenchyma, vessel blurring, focal sparing, and 
narrowing of the lumen of the hepatic veins, according to international 
guidelines45,106 .Previous studies indicated that ultrasonography can detect 
and quantitate hepatic fat accumulation with an accuracy similar to that of 
computed tomography and liver biopsy.107 
The upper limit of normal liver size was 15 cm in the longitudinal plane; any 
measurement above this was considered hepatomegaly. Mild hepatomegaly 
was defined as liver size >15-18 cm in the longitudinal plane. 
The presence of steatosis was graded from mild to severe and for calculation 
purposes all grades were taken as positive fatty liver. 
All the images were reviewed by another radiologist to minimise observer 
errors. 
The  L & T Ultrasound machine used had a 3.5 mhz probe. 
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Liver biopsy was done using the Menghini technique after adopting the 
standard protocols and after a fully informed consent from the patient. A 
platelet count was done, coagulation profile was done and vitamin K was 
given as intramuscular injection for 3 days prior to the procedure. 
 
STATISTICAL ANALYSIS 
Statistical analysis of the data obtained from the study was done using the 
‘z’ test or ‘normal’ test to compare the mean values of two groups of 
participants. The chi- square test was used to compare the prevalence 
between two groups. The calculations were done for 5% level of 
significance.(P=0.05) 
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              REVIEW OF LITERATURE 
The incidence of diabetes mellitus is ever increasing and Diabetes 
mellitus is the common cause of increased morbidity and mortality. 
Diabetes mellitus affects many organs and systems in our body.  
 The liver plays a pivotal role in the metabolism of carbohydrates and 
lipids; affection of liver is common in diabetes. Sometimes liver disease may 
give rise to abnormalities in glucose homeostasis, and finally certain diseases 
of liver might be present coincidentally with diabetes.1 
LIVER DISEASE IN DIABETES MELLITUS 
1. Liver disease occurring as a consequence of diabetes mellitus  
• Glycogen deposition  
• Steatosis and nonalcoholic steatohepatitis (NASH)  
• Fibrosis and cirrhosis  
• Biliary disease, cholelithiasis, cholecystitis  
• Complications of  therapy of  diabetes (cholestatic and 
necroinflammatory)  
2.  Abnormalities of glucose homeostasis occurring as a complication of 
liver disease can be present in  
• Hepatitis  
• Cirrhosis  
• Hepatocellular carcinoma  
• Fulminant hepatic failure  
• Post orthotopic liver transplantation  
3. Liver disease occurring coincidentally with diabetes mellitus and 
abnormalities of glucose homeostasis  
• Hemochromatosis  
• Glycogen storage diseases  
• Autoimmune biliary disease  
Hepatic fat accumulation is a well-recognized complication of diabetes with 
a reported frequency of 40–70%. Unfortunately, associated obesity is a 
frequently occurring confounding variable. Type 1diabetes is not associated 
with fat accumulation if glycemia is well controlled, but type 2 diabetes may 
have a 70% correlation regardless of blood glucose control.1  
Nonalcoholic fatty liver disease refers to a broad spectrum of liver disease 
ranging from steatosis (bland fatty infiltration of hepatocytes) to 
nonalcoholic steatohepatitis (steatosis plus inflammation, necrosis, or 
fibrosis) to cirrhosis and, in some patients, to end-stage liver disease and 
hepatocellular carcinoma. These facts have been documented in studies done 
by Lee R .G et al (1989)8 and Powell E .E et al 9(1990) 
  
In 1980, Ludwig and colleagues coined the term Non Alcoholic Fatty 
liver Disease (NAFLD) and Non Alcoholic Steato- Hepatitis (NASH). Many 
names have since been proposed for this condition but this terminology has 
been widely accepted worldwide. 
 
 
 
 
 
 
 
 
 
NONALCOHOLIC FATTY LIVER DISEASE 
 
Nonalcoholic fatty liver disease is an increasingly recognized condition that 
may progress to end-stage liver disease. The pathological picture resembles 
that of alcohol-induced liver injury, but it occurs in patients who do not 
abuse alcohol.2,3 A variety of terms have been used to describe this entity, 
including fatty-liver hepatitis, nonalcoholic Laënnec's disease, diabetes 
hepatitis, alcohol-like liver disease, and nonalcoholic steatohepatitis. 
Nonalcoholic fatty liver disease is becoming the preferred term, and it refers 
to a wide spectrum of liver damage, ranging from simple steatosis to 
steatohepatitis, advanced fibrosis, and cirrhosis. 
 
The clinical implications of nonalcoholic fatty liver disease are derived 
mostly from its common occurrence in the general population and it’s 
potential to progress to cirrhosis and liver failure. Nonalcoholic fatty liver 
disease should be differentiated from steatosis, with or without hepatitis, 
resulting from secondary causes, because these conditions have distinctly 
different pathogeneses and outcomes. 
 
 
 
 
The causes of FATTY LIVER with the exception of alcohol are:4 
MACROVESICULAR (large fat droplets in hepatocytes) 
Insulin resistance. 
Syndrome X (obesity, diabetes, hypertriglyceridemia, hypertension.) 
Lipodystrophy. 
Dysbetalipoprotenemias. 
Protein calorie malnutrition,  Starvation. 
Total parenteral nutrition, jejuno-ileal bypass 
Rapid weight loss 
Drugs: e.g. Methotrexate, Aspirin, Vitamin A, Glucocorticoids, 
Amiodarone,Calcium Channel Blockers, Synthetic Estrogen And Nucleoside 
Analogues 
Inflammatory bowel disease 
 
MICROVESICULAR (small fat droplets in hepatocytes) 
Reye’s syndrome 
Acute fatty liver of pregnancy 
Jamaican vomiting sickness 
Drugs e.g. Valproic Acid, Tetracycline, Nucleoside Analogues 
Environmental hepatotoxins (e.g. phosphorus, petrochemicals) 
 
 
 EPIDEMIOLOGIC FEATURES  
RISK FACTORS  
Obesity, Type 2 Diabetes Mellitus, and Hyperlipidemia are coexisting 
conditions frequently associated with nonalcoholic fatty liver disease. The 
reported prevalence of obesity in several series of patients with nonalcoholic 
fatty liver disease varied between 30 and 100 percent, the prevalence of type 
2 diabetes varied between 10 and 75 percent, and the prevalence of 
hyperlipidemia varied between 20 and 92 percent.2,5,6,7,8,9,10,11,12,13,14,15,16  
The prevalence of nonalcoholic fatty liver disease increases by a factor 
of 4.6 in obese people, defined as those with a Body-Mass Index of at least 
30.17 Regardless of body-mass index, the presence of type 2 diabetes mellitus 
significantly increases the risk and severity of nonalcoholic fatty liver 
disease.18,19 Truncal obesity seems to be an important risk factor for 
nonalcoholic fatty liver disease, even in patients with a normal body-mass 
index.20 About half of patients with hyperlipidemia were found to have 
nonalcoholic fatty liver disease on ultrasound examination in one study.21 
Hypertriglyceridemia rather than hypercholesterolemia may increase the risk 
of nonalcoholic fatty liver disease.21 
Among people who are not obese and do not have diabetes, risk 
factors for NAFLD are impaired fasting glycemia, hypertriglyceridemia, 
hyperuricemia, central obesity, hypertension and low levels of high-density 
lipoprotein (HDL) cholesterol.22 
A family history of steatohepatitis or cryptogenic cirrhosis has also 
been implicated as a risk factor for this disorder.23. Nonalcoholic fatty liver 
disease may affect persons of any age and has been described in most racial 
groups. In most series, the typical patient with nonalcoholic fatty liver 
disease is a middle-aged woman, 2, 5, 6,7,8,13,16. but some have found a higher 
prevalence of nonalcoholic fatty liver disease in males than in 
females.24,25,,26,27.  
PREVALENCE 
Nonalcoholic fatty liver disease affects 10 to 24 percent of the general 
population in various countries. The prevalence increases to 57.5 percent26 to 
74 percent17, 27 in obese persons. 
Nonalcoholic fatty liver disease is a common explanation for abnormal liver-
test results in blood donors, and it is the cause of asymptomatic elevation of 
aminotransferase levels in up to 90 percent of cases once other causes of 
liver disease are excluded.28 
Diabetes mellitus affects 7.8 percent of the U.S. adult population,29 whereas 
about 50 percent (range, 21 to 78 percent)30 of patients with diabetes  have 
nonalcoholic fatty liver disease. The association of diabetes and obesity may 
pose an added risk: among severely obese patients with diabetes, 100 percent 
were found to have at least mild steatosis, 50 percent had steatohepatitis, and 
19 percent had cirrhosis.31 
 
CLINICAL MANIFESTATIONS  
Clinical Features  
NAFLD is usually asymptomatic, although fatigue and discomfort in 
the right upper quadrant of the abdomen may be reported.32. The majority 
(56%–79%) of patients are overweight (body mass index [BMI] > 25 kg/m2), 
and one-third have the metabolic syndrome.33,34,35 Lean patients (BMI 25 
kg/m2) usually have at least one metabolic risk factor.33 Hepatomegaly may 
be present, although signs of chronic liver disease are uncommon.32.,36  
Hepatomegaly is the only physical finding in most patients. 
Acanthosis nigricans may be found in children with nonalcoholic fatty liver 
disease.33,37 Findings of chronic liver disease and diminished numbers of 
platelets suggest that advanced disease with cirrhosis is present. A high 
proportion of patients with cryptogenic cirrhosis share many of the clinical 
and demographic features of patients with nonalcoholic fatty liver disease,38 
suggesting that their cryptogenic cirrhosis is unrecognized nonalcoholic fatty 
liver disease. 
Common symptoms and signs of 400 subjects with NAFLD (Data 
from the NAFLD clinic at Virginia Commonwealth University, previously 
unpublished data).86 
 
Symptoms and signs NAFLD 
(n=75) 
% 
NASH 
(n=325) 
% 
Asymptomatic 60 55 
Fatigue 30 45 
Pruritus 2 4 
Right upper quadrant 
discomfort 
30 32 
Edema 4 5 
Hepatomegaly 22 28 
Stigmata of chronic 
liver disease 
8 10 
Obesity 65 60 
Diabetes 45 50 
Hypertension 60 65 
LABORATORY ABNORMALITIES  
Mildly to moderately elevated serum levels of aspartate 
aminotransferase, alanine aminotransferase, or both are the most common 
and often the only laboratory abnormality found in patients with 
nonalcoholic fatty liver disease. The ratio of aspartate aminotransferase to 
alanine aminotransferase is usually less than 1, but this ratio increases as 
fibrosis advances, leading to a loss of its diagnostic accuracy in patients with 
cirrhotic nonalcoholic fatty liver disease.16 Serum alkaline phosphatase, -
glutamyltransferase, or both are above the normal range in many patients, 
although their degree of elevation is less than that seen in alcoholic 
hepatitis.6,7,13 An ALT or AST value >300IU/l should raise suspicion of 
alternate pathology.40,2 The degree of abnormality is usually moderate and 
does not exceed 2–3 times the upper limit of normal values.15,16 
Unfortunately, none of these tests are sensitive or specific enough to 
establish a diagnosis of NAFLD with great accuracy 
 Other abnormalities, including hypoalbuminemia, a prolonged 
prothrombin time, and hyperbilirubinemia, may be found in patients with 
cirrhotic-stage nonalcoholic fatty liver disease. 
Ferritin levels are increased in 20%–50% of patients, and elevated 
transferrin saturation (> 55%) is present in 5%– 10%.,41 
 Autoantibodies are identified in 23%–36% of NAFLD patients and 
are associated with more advanced fibrosis.42,43  
However, in studies of subjects with persistently elevated ALT values 
without an obvious explanation, NAFLD was found in only 70–80% of cases 
and 20–30% of subjects were found to have an alternate cause for their 
elevated liver enzymes 44,. Of note, 5.9% of subjects had a normal liver 
despite a complete evaluation. 
IMAGING STUDIES  
On ultrasonography, fatty infiltration of the liver produces a diffuse increase 
in echogenicity as compared with that of the kidneys. Regardless of the 
cause, cirrhosis has a similar appearance on ultrasonography. 
Ultrasonography has a sensitivity of 89 percent and a specificity of 93 
percent in detecting steatosis and a sensitivity and specificity of 77 
percent and 89 percent, respectively, in detecting increased fibrosis.45 
Fatty infiltration of the liver produces a low-density hepatic parenchyma on 
computed tomographic (CT) scanning. Steatosis is diffuse in most patients 
with nonalcoholic fatty liver disease, but occasionally, it is focal.  
 
Sonography of fatty liver may be varied depending on the amount of fat and 
whether deposits are diffuse or focal.46  
Diffuse steatosis may be:47 
Mild:  minimal diffuse increase in hepatic echogenicity; normal 
visualization of diaphragm and intrahepatic vessel borders. 
Moderate:  moderate increase in hepatic echogenicity; slightly impaired 
visualization of intrahepatic vessels and diaphragm. 
Severe: marked increase in echogenicity; poor penetration of the posterior 
segment of right lobe of liver and poor or non visualization of the hepatic 
vessels and diaphragm. 
Sonographic features of focal fatty change are: 
 Focal fat may show rapid change with time both in appearance and 
resolution, it does not alter the course or caliber of regional blood vessels, 
does not produce contour abnormalities, and the preferred site for both focal 
fat deposition and focal sparing is the area anterior to the portal vein at the 
porta hepatis. Some times focal fat may produce geographic map-like 
boundaries. 
 
CT imaging of the liver provides a more specific method for the non-
invasive diagnosis of NAFLD. Hepatic steatosis decreases the CT 
attenuation of the liver. When the hepatic parenchymal attenuation is 10 or 
more Hounsfield units lower than the spleen on a non-contrast-enhanced 
scan, a diagnosis of hepatic steatosis can be made. When intravenous 
contrast is administered, the hepatic enhancement lags behind the spleen and 
the liver-to-spleen attenuation differential exceeds 20 Hounsfield units.48 
While these features allow hepatic steatosis to be defined with a 76% 
positive predictive value 49, 
Magnetic resonance spectroscopy allows a quantitative assessment of 
fatty infiltration of the liver,50. and a minimum of 5%–10% steatosis by 
weight is considered a requirement for the diagnosis of NAFLD.39. 
The sensitivity of each imaging method increases with the degree of 
fatty infiltration, with at least 33% steatosis being optimal for detection.49. 
 
 
 
 
 
HISTOLOGIC FINDINGS  
Nonalcoholic fatty liver disease is histologically indistinguishable 
from the liver damage resulting from alcohol abuse. Liver-biopsy features 
include steatosis, mixed inflammatory-cell infiltration, hepatocyte ballooning 
and necrosis, glycogen nuclei, Mallory's hyaline, and fibrosis. The presence 
of these features, alone or in combination, accounts for the wide spectrum of 
nonalcoholic fatty liver disease. Portal tracts are relatively spared from 
inflammation, although children with nonalcoholic fatty liver disease may 
show a predominance of portal inflammation as opposed to a lobular 
infiltrate.12 Mallory's hyaline is notably sparse or absent in children with 
nonalcoholic fatty liver disease.12,33,37 In some patients with cirrhosis, the 
features of steatosis and necroinflammatory activity may no longer be 
present.9,10  
A finding of fibrosis in nonalcoholic fatty liver disease suggests more 
advanced and severe liver injury. According to a number of cross-sectional 
studies including a total of 673 liver biopsies,2,,5,,7,8,9,10,11,15,16,51,52 some degree 
of fibrosis is found in up to 66 percent of patients at the time of diagnosis, 
whereas severe fibrosis (septal fibrosis or cirrhosis) is found in 25 percent 
and well-established cirrhosis is found in 14 percent.  
The combination of steatosis, infiltration by mononuclear cells or 
polymorphonuclear cells (or both), and hepatocyte ballooning and spotty 
necrosis is known as nonalcoholic steatohepatitis. Most patients with this 
type of nonalcoholic fatty liver disease have some degree of fibrosis, whereas 
Mallory's hyaline may or may not be present. The severity of steatosis can be 
graded on the basis of the extent of involved parenchyma .53.A system that 
unifies the lesions of steatosis and necroinflammation into a "grade" and 
those of the types of fibrosis into a "stage" has recently been proposed .53.  
 
PATHOGENESIS 105 
The pathogenesis of nonalcoholic fatty liver disease has remained 
poorly understood since the earliest description of the disease. Much current 
thinking remains hypothetical, since the mechanism or mechanisms are still 
being worked out. It is not yet understood why simple steatosis develops in 
some patients, whereas steatohepatitis and progressive disease develop in 
others; differences in body-fat distribution or antioxidant systems, possibly 
in the context of a genetic predisposition, may be among the explanations.  
A net retention of lipids within hepatocytes, mostly in the form of 
triglycerides, is a prerequisite for the development of nonalcoholic fatty 
liver disease. The primary metabolic abnormalities leading to lipid 
accumulation are not well understood, but they could consist of alterations in 
the pathways of uptake, synthesis, degradation, or secretion in hepatic lipid 
metabolism resulting from insulin resistance.  
Possible Mechanisms of Pathogenesis of Nonalcoholic Fatty Liver Disease:  
 
 
As shown in figure A, hepatic fatty acids are normally esterified into 
triglycerides, some of which are exported out of hepatocytes as very-low-
density lipoproteins (VLDL). The increased level of lipids, mostly in the 
form of triglycerides, within hepatocytes in patients with nonalcoholic fatty 
liver disease results from an imbalance between the enzyme systems that 
promote the uptake and synthesis of fatty acids and those that promote 
the oxidation and export of fatty acids. 
 In figure B, insulin resistance (owing to inhibition of tumor necrosis 
factor [TNF- ], Rad, PC-1, eptin, and fatty acids) leads to the 
accumulation of fat in hepatocytes by two main mechanisms: lipolysis, 
which increases circulating fatty acids, and hyperinsulinemia. Increased 
uptake of fatty acids by hepatocytes leads to mitochondrial -oxidation 
overload, with the consequent accumulation of fatty acids within 
hepatocytes. Fatty acids are substrates and inducers of the microsomal 
lipoxygenases cytochrome P-450 2E1 and 4A.54,55 The level of cytochrome 
P-450 2E1 is invariably increased in the liver of patients with steatohepatitis 
and may result in the production of free oxygen radicals capable of inducing 
lipid peroxidation of hepatocyte membranes.54  Hyperinsulinemia resulting 
from insulin resistance increases the synthesis of fatty acids in hepatocytes 
by increasing glycolysis and favors the accumulation of triglycerides within 
hepatocytes by decreasing hepatic production of apolipoprotein B-100. 
 
Figure C shows the relation between microsomal -oxidation, 
peroxisomal -oxidation, and mitochondrial -oxidation, as well as the 
regulatory role of peroxisome-proliferator–activated receptor (PPAR- ) 
ligand. Microsomal -oxidation of fatty acids generates dicarboxylic fatty 
acids, which are further degraded by peroxisomal -oxidation. Peroxisomal 
-oxidation generates chain-shortened acyl–coenzyme A. Very-long-chain 
fatty acids are converted to acyl–coenzyme A by the action of acyl–
coenzyme A synthetase. Acyl–coenzyme A serves as a substrate for 
peroxisomal oxidation, but if left unmetabolized, it functions as a PPAR-  
ligand. PPAR-  controls the induction of genes involved in microsomal, 
peroxisomal, and mitochondrial fatty-acid oxidation systems in liver, and it 
may also promote hepatic synthesis of uncoupling protein-2.56 The role of 
this protein in the pathogenesis of nonalcoholic fatty liver disease remains 
uncertain. It may help inhibit hepatocyte apoptosis, but it may also increase 
the vulnerability of fatty hepatocytes to subsequent injury when exposed to 
secondary insults such as endotoxin or TNF- .56,57,32 
 
In figure D, mitochondrial reactive oxygen species promote 
progression from steatosis to steatohepatitis and fibrosis by three main 
mechanisms: lipid peroxidation, cytokine induction, and Fas ligand 
induction. Reactive oxygen species trigger lipid peroxidation, which causes 
cell death and releases malondialdehyde (MDA) and 4-hydroxynonenal 
(HNE).58 MDA and HNE cause cell death; cross-link proteins, leading to the 
formation of Mallory's hyaline59; and activate stellate cells, promoting 
collagen synthesis.34 HNE has chemotactic activity for neutrophils, 
promoting tissue inflammation.35 Reactive oxygen species also induce the 
formation of the cytokines TNF- , transforming growth factor (TGF- ), and 
interleukin-8. TNF-  and TGF-  cause caspase activation and hepatocyte 
death.36,60 TGF-  activates collagen synthesis by stellate cells34 and activates 
tissue transglutaminase, which cross-links cytoskeletal proteins, promoting 
the formation of Mallory's hyaline. Interleukin-8 is a potent chemoattractant 
for human neutrophils.61 The TNF-  induced by reactive oxygen species 
further impairs the flow of electrons along the respiratory chain in 
mitochondria.62 Mitochondrial reactive oxygen species can deplete hepatic 
antioxidants, allowing accumulation of more reactive oxygen species.63,64 
Mitochondrial reactive oxygen species cause expression of the Fas ligand in 
hepatocytes, which normally express the membrane receptor Fas.65 The Fas 
ligand on one hepatocyte can then interact with Fas on another hepatocyte, 
causing fractional killing. 
Insulin resistance is the most reproducible factor in the development of 
nonalcoholic fatty liver disease.66 The molecular pathogenesis of insulin 
resistance seems to be multifactorial, and several molecular targets involved 
in the inhibition of insulin action have been identified. Insulin resistance 
leads to fat accumulation in hepatocytes by two main mechanisms: 
lipolysis and hyperinsulinemia . 
Clinically significant amounts of dicarboxylic acids, which are potentially 
cytotoxic, can be formed by microsomal -oxidation. This pathway of fatty-
acid metabolism is closely related to mitochondrial -oxidation and 
peroxisomal -oxidation. Deficiency of the enzymes of peroxisomal -
oxidation has been recognized as an important cause of microvesicular 
steatosis and steatohepatitis.67 Deficiency of acyl–coenzyme A oxidase 
disrupts the oxidation of very-long-chain fatty acids and dicarboxylic acids, 
leading to extensive microvesicular steatosis and steatohepatitis. Loss of this 
enzyme also causes sustained hyperactivation of peroxisome-proliferator–
activated receptor-  (PPAR- ), leading to transcriptional up-regulation of 
PPAR- –regulated genes.67 PPAR-  has been implicated in promoting 
hepatic synthesis of uncoupling protein-2, which is expressed in the liver of 
patients with nonalcoholic fatty liver disease.56 
Increased intrahepatic levels of fatty acids provide a source of oxidative 
stress, which may in large part, be responsible for the progression from 
steatosis to steatohepatitis to cirrhosis. Mitochondria are the main cellular 
source of reactive oxygen species, which may trigger steatohepatitis and 
fibrosis by three main mechanisms: lipid peroxidation, cytokine induction, 
and induction of Fas ligand. Patients with steatohepatitis have ultrastructural 
mitochondrial lesions, including linear crystalline inclusions in 
megamitochondria.68 This mitochondrial injury is absent in most patients 
with simple steatosis and in healthy subjects.69. Patients with steatohepatitis 
slowly resynthesize ATP in vivo after a fructose challenge, which causes 
acute hepatic ATP depletion.70 This impaired ATP recovery may reflect the 
mitochondrial injury found in patients with steatohepatitis.68,69 . 
Thus, although symptoms of liver disease rarely develop in patients with 
fatty liver who are obese, have diabetes, or have hyperlipidemia, the steatotic 
liver may be vulnerable to further injury when challenged by additional 
insults. This has led to the presumption that progression from simple 
steatosis to steatohepatitis and to advanced fibrosis results from two 
distinct events.71 First, insulin resistance leads to the accumulation of fat 
within hepatocytes, and second, mitochondrial reactive oxygen species 
cause lipid peroxidation, cytokine induction, and the induction of Fas ligand.  
 
 
 
 
 
 
 
DIAGNOSIS  
The diagnosis of nonalcoholic fatty liver disease is usually suspected 
in persons with asymptomatic elevation of aminotransferase levels, 
radiologic findings of fatty liver, or unexplained persistent hepatomegaly. 
The clinical diagnosis and liver tests have a poor predictive value with 
respect to histologic involvement.72 Imaging studies, although of help in 
determining the presence and amount of fatty infiltration of the liver, cannot 
be used to accurately determine the severity of liver damage. 
Liver biopsy is considered as best method for the detection of hepatic 
steatosis and it can also detect steatohepatitis.  
The diagnosis of nonalcoholic fatty liver disease requires the exclusion 
of alcohol abuse as the cause of liver disease; a daily intake as low as 20 g in 
females and 30 g in males may be sufficient to cause alcohol-induced liver 
disease in some patients (350 ml [12 oz] of beer, 120 ml [4 oz] of wine, and 
45 ml [1.5 oz] of hard liquor each contain 10 g of alcohol).73,74,75 Other 
causes, such as viruses, autoimmune responses, metabolic or hereditary 
factors, and drugs or toxins, should be ruled out. The decision on how 
extensive the serologic workup should be must be individualized. 
Even though liver biopsy is considered to be the best, some advocate 
that there are several drawbacks in using liver biopsy for this purpose. This 
procedure is invasive, costly, and prone to complications, some minor, such 
as pain, others more severe with a recorded risk of death of 0.01%.76,77,78 
Notably, just as is the case in other chronic liver diseases, there is 
considerable sampling variability (40% for fibrosis staging), and a high intra 
and inter-pathologist variability.79,80 Most importantly, the number of 
patients at risk for NAFLD is high enough that liver biopsy is not a practical 
and efficient tool for identifying those at risk of advanced fibrosis. Indeed an 
estimated 15 to 20% of the Western European population has steatosis 81 
while more than half of Americans are overweight or obese.  
So the diagnostic workup needs to be individualized and decisions 
taken accordingly.  
Some newer methods are now emerging for the diagnosis of hepatic 
steatosis and steatohepatitis such as the H magnetic resonance spectroscopy 
And the fibrosure test for the detection of fibrosis. These tests may in course 
of time serve as a better noninvasive method for the detection of NAFLD.  
  
 
 
 
NATURAL HISTORY  
The natural history of nonalcoholic fatty liver disease is not well defined, but 
it seems to be determined by the severity of histologic damage. In five series, 
54 of 257 patients with nonalcoholic fatty liver disease underwent liver 
biopsy during an average follow-up of 3.5 to 11 years.8,9,10,11,52 Of these 
patients, 28 percent had progression of liver damage, 59 percent had 
essentially no change, and 13 percent had improvement or resolution of liver 
injury. Progression from steatosis to steatohepatitis25,79 and to more advanced 
fibrosis8,9,11,52 or cirrhosis8,9,11,52 has been recognized in several cases. Some 
of the few deaths that occurred among the 257 patients were liver-related, 
including one from hepatocellular cancer. Thus, many patients with 
nonalcoholic fatty liver disease have a relatively benign course, whereas in 
some others, the disease progresses to cirrhosis and its complications.  
Patients found to have pure steatosis on liver biopsy seem to have the best 
prognosis within the spectrum of nonalcoholic fatty liver disease,11 whereas 
features of steatohepatitis or more advanced fibrosis are associated with a 
worse prognosis.9,15,52 In one study,52 progression of liver fibrosis occurred 
only in patients with necrosis and inflammatory infiltration on liver biopsy. 
In another study,15 36 percent of patients with nonalcoholic fatty liver disease 
died after a mean follow-up of 8.3 years; liver-related diseases were the 
second most common cause of death, exceeded only by cancer. There was a 
trend toward more liver-related deaths among patients with steatohepatitis, 
which can be explained by the higher prevalence of cirrhosis among these 
patients.15 Some data suggest that the coexistence of steatosis with other liver 
diseases, such as hepatitis C virus infection, could increase the risk of 
progression of the liver disease.83 The natural history of cirrhosis resulting 
from nonalcoholic fatty liver disease has not been completely defined. In a 
recent study,84 only 2.9 percent of 546 liver-transplantation procedures 
performed in a single center were for end-stage steatohepatitis.  
This suggests that although nonalcoholic fatty liver disease is 
common, only a minority of patients will require liver transplantation.  
 
 
 
 
 
 
 
 
 
 
 
 
TREATMENT 
Many clinical trials are going on to find out an effective method of 
treatment of Nonalcoholic Fatty Liver Disease, many treatment options have 
been suggested and they are: 
1. Treatment of associated disorders 
 Gradual weight loss, Control of diabetes, Control of dyslipidemia 
 
2. Potential pharmacological approaches 
Improved insulin resistance 
 Metformin, Thiazolidinediones: rosiglitazone, pioglitazone. 
Improved dyslipidemia 
 Clofibrate, Gemfibrozil, Atorvastatin, Probucol. 
Antioxidants 
 Tocopherol, Tocopherol/ascorbic acid, Betaine, Ursodeoxycholic acid, S-
adenosylmethionine. 
 
3. Liver transplantation 
 
  
 
 
 
 PATHOGENESIS OF NAFLD AND NASH- “THE TWO HIT HYPOTHESIS” 
First hit causes development of fatty liver and the second hit results in 
inflammation. 
  
 
 
RESULTS AND OBSERVATIONS 
A total of 129 patients diagnosed with type 2 Diabetes mellitus for 3 years and 
more were included in this study after applying the selection criteria. Most of 
them belonged to the low and middle socioeconomic groups. 
Out of the 129 participants 70 were females and 59 were males.               
SEX DISTRIBUTION
59
70
MALE FEMALE
 
 
 
The age of the participants varied from 40 to 75 years and the mean age was 
52.45 + or – 7.15 years. 
 
Out of the total 129 participants 63 persons (48.8%) had 
ultrasonographically detected fatty liver. Most of them had moderate or severe 
steatosis ultrasonogram wise. They were called as the NAFLD (Non Alcoholic 
Fatty Liver Disease) group.  Of these 63 persons 41 were females and 22 were 
males.   
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 Female(total 70) Male (total 59) 
 
P value 
NAFLD in USG(63) 41 (58.57%) 22 (37.29%) < 0.05 
Normal USG(66) 29 (41.43%) 37 (62.71%)  
 
The duration of Diabetes varied from 3 to 20 years in the study group with 
a mean value of 5.48+ or – 3.57 years. 
The mean duration of Diabetes in the fatty liver group was 5.47+ or – 3.19 
years as compared to 5.48+ or – 3.94 years in the normal liver group. There was 
no significant difference between the NAFLD group and the normal group 
duration wise (P value >0.05). 
The age wise distribution of patients with and without fatty liver in 
Ultasonogram is as follows 
Age group Total (129)  NAFLD (63) Normal (66) 
40-49 years  45 19 (30.2%) 26 (39.4%) 
50-59 years 60 32 (50.8%) 28 (42.4%) 
> 60 years 24 12 (19.0%) 12 (18.2%) 
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CLINICAL FEATURES  
Most of the persons with fatty liver were asymptomatic, i.e. 38 out of total 
63. The next common symptom was right upper quadrant discomfort, which was 
present in 14 out of 63 patients, 2 persons in the fatty liver group had complaint 
of abdominal distension, and no patient had the complaint of jaundice, 16 persons 
had a feeling of generalized weakness and malaise. 
SYMPTOMS
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Clinical examination of abdomen revealed hepatomegaly in 8 patients with 
fatty liver and 2 patients in the normal group. No patients in both groups had 
splenomegaly or ascites. Ultrasonography showed hepatomegaly in 12 out of 63 
persons with fatty liver compared to 2 out of 66 persons in the normal liver group. 
 
BODY MASS INDEX 
The Body Mass Index varied ( BMI ) from 17 to 37 kg/m2 with a mean of  
a Body Mass Index of 23.60+or-3.17 kg/m2.A BMI of 25 kg/m2 was taken as a 
cut off between overweight and obese, 88 persons had a BMI below 25 kg/m2 and 
41 persons had a BMI of above 25 kg/m2. Only 4 persons had a BMI of more 
than 30 kg/m2 all of them had fatty liver. Out of the patients with a BMI of 
more than 25 kg/m2 (total 41) 33 persons had fatty liver detected in 
ultrasonogram. In the low BMI group (total 88) 30 persons had 
Ultrasonographically detected fatty liver.  
Mean BMI values: 
NAFLD group Normal group P value 
24.97+ or _3.54 (kg/m2 ) 22.29+ or _2.05(kg/m2 ) < 0.05 
 
 
BMI (kg/m2 )  NAFLD GROUP(63) NORMAL USG (66) 
<25 (88) 30 (47.62%) 58(87.88%) 
>25 (41) 33 (52.38%) 8 (12.12%) 
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LABORATORY INVESTIGATIONS  
BLOOD SUGAR 
All the patients had a random, fasting and postprandial blood sugar 
estimation done. 
  The number of patients with and without fatty liver in the different fasting 
blood sugar categories is as follows. 
FBS (mg/dl) TOTAL FATTY LIVER NORMAL USG 
< 125 23 8 15
125 TO 150 47 24 23 
150 TO 175 33 16 17 
>175 26 15 11 
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The mean fasting blood sugar in the above two categories are:  
NAFLD group Normal group P value 
156.19+ or _36.53mg/dl 146.67+ or _32.38mg/dl > 0.05 
LIVER FUNCTION TESTS 
The liver function tests done included the Serum Transaminases, Serum Alkaline 
Phosphatase, Serum Total Bilurubin and Total Proteins 
The normal values of serum transaminases was 5 to 35 IU/l. The normal value of 
Serum Alkaline Phosphatase is up to 150 IU/l. the participants were categorized 
into a low Transaminase level group of 25 IU/l or below and a high normal and 
increased Transaminase level group with a value of more than 25 IU/l.  
 
SGOT LEVELS: 
SGOT levels Total (129) NAFLD group(63) Normal group(66)
< 25 IU/L  96 40 (63.5%) 53 (80.3%) 
25- 35 IU/L 20 11 (22.2%)  9 (13.6%) 
> 35 IU/L 13  9 (14.3%)  4 (6.1%)  
 
 
 
Mean SGOT values: 
NAFLD group  Normal group P value 
25.02+ or _20.64 IU/L 18.41+ or _11.97 IU/L < 0.05 
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SGPT 
Out of the total of 63 persons who had Ultrasonographically proven fatty 
liver 28 persons had an SGPT value of more than 25IU/L and 13 had an SGPT 
value of more than 35 IU/l. 
Out of out of a total of 66 persons who had normal liver in 
Ultrasonography 12 persons had an SGPT value of more than 25IU/L and 3 
persons had an SGPT value of more than 35 IU/l. 
Mean SGPT Values: 
NAFLD group Normal group P value 
29+ or _28.35 IU/L 17.47+ or _10.02 IU/L < 0.05 
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ALKALINE PHOSPHATASE 
Out of the total of 63 persons who had Ultrasonographically proven fatty 
liver 20 (31.7%) persons had a Serum Alkaline Phosphatase value of more than 
150 IU/L and 4 individuals had a value of more than 250 IU/l. 
Out of a total of 66 persons who had normal liver in Ultrasonography 19 
(28.78%) persons had a Serum Alkaline Phosphatase value of more than 150 and 
1 person had a Serum Alkaline Phosphatase value of more than 250 IU/l. 
 
Mean Alkaline phosphatase values: 
NAFLD group Normal group P value 
123.97+ or _66.13 IU/L 106.52+ or _68.75 IU/L > 0.05 
 
0
10
20
30
40
50
N
o 
of
 p
at
ie
nt
s
FATTY LIVER GROUP NON FATTY LIVER GROUP
ALKALINE PHOSPHATASE
< 150 (90 PTS) > 150 (39 PTS)
 
SERUM BILURUBIN: 
The mean Serum total biluribin in the NAFLD group was 1.10 mg/dl and 
the Serum total Bilurubin in the normal group was 0.84 mg/dl. There was no 
significant difference in levels of Serum bilurubin between the two groups. 
 
TOTAL PROTEINS: 
The mean value of Total Protein in the NAFLD group was 6.43 gm and in 
the normal group it was 6.48 gm.There was no significant difference in levels of 
Total Protein between the NAFLD and normal liver groups. 
 
 
 
 
 
 
 
 
 
 
 
 
 
FASTING LIPID PROFILE 
The lipid done after an overnight fast of 12 hours included Total 
Cholesterol, Serum Triglycerides (TGL), Serum High Density Lipoprotein (HDL) 
and the Low Density Lipoprotein (LDL) value was calculated using the 
Friedwald formula. 
According to the ATP III guidelines for the classification and treatment of 
lipid disorders, the levels of lipoproteins were considered abnormal if total 
cholesterol was above 200, if serum triglyceride level was above 150 mg/dl, 
serum HDL level was below 50 and LDL levels were above 100. 
 
TOTAL CHOLESTEROL: 
A total of 69 out of 129 had a high Total Cholesterol value. Among the 
NAFLD group out of the total 63 patients 44 (69.84%) had a Total Cholesterol 
value of more than 200 and among the normal liver group 25 (37.88%) out of the 
66 had a Total cholesterol value of more than 200. 
 
The mean total cholesterol values are as follows: 
NAFLD group Normal group P value 
225.33+ or _43.95 mg/dl 
 
192.67+ or _35.38 mg/dl < 0.05 
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TRIGLYCERIDES 
Out of the 63 patients in the NAFLD group 38 (60.32%) patients had a 
triglyceride level of more than 150 mg/dl of the 66 patients in the normal liver 
group 28 (42.42%) persons had a triglyceride level of more than 150 mg/dl. 
 The mean triglyceride levels: 
NAFLD group Normal group P value 
235.82 +or_ 105.18 mg/dl
 
155.81+ or _61.08 mg/dl < 0.05 
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HDL 
Out of the 63 patients in the NAFLD group 40 patients had a HDL level of 
less than 50 mg/dl of the 66 patients in the normal liver group 31 persons had a 
HDL level of less than 50 mg/ dl. 
 The mean HDL levels:  
NAFLD group Normal group P value 
46.24+ or _8.03 mg/dl 
 
49.21+ or _9.93 mg/dl > 0.05 
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LDL 
The LDL levels varied from 52 to 273mg/dl and a total of 86 patients had 
LDL levels above 100 mg/dl. In the fatty liver group 45 out of the 63 persons had 
elevated LDL values above 100 mg/dl. In the normal liver group 41 out of the 66 
persons had an elevated LDL level of more than 100 mg/dl. 
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MEAN LDL VALUES: 
NAFLD group Normal group P value 
128.52+ or _41.66 mg/dl 
 
111.45+ or _27.80 mg/dl < 0.05 
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ABSTRACT OF STATISTICAL ANALYSIS 
MEAN VALUES: 
PARAMETER 
NAFLD GROUP 
 
(n=63) 
NORMAL USG 
GROUP 
(n=66) 
STATISTICAL 
SIGNIFICANCE AT 
5% LEVEL 
DURATION OF 
DIABETES (yrs) 
 
5.47 +or– 3.19 5.48 +or- 3.94 
No significant difference
(P value >0.05) 
BMI (kg/m2) 24.97 +or- 3.54 2.29 +or- 2.05 
 Significant difference 
  present 
 (P value <0.05) 
SGOT (i u/l) 25.02 +or- 20.64 18.41 +or- 11.97 
Significant difference 
  present 
 (P value <0.05) 
SGPT (i u/l) 29.00+or-28.35 17.47+or-10.02 
Significant difference 
  present 
 (P value <0.05) 
ALP  (i u/l) 
 
 
123.97+or-66.13 106.52+or-68.75 
No significant difference
(P value >0.05) 
BILURUBIN 
(mg/dl) 
 
1.10+or-1.12 0.84+or-0.36 
No significant difference
(P value >0.05) 
TOTAL 
CHOLESTEROL 
(mg/dl) 
225.33+or-43.95 192.67+or-35.38 
Significant difference 
  present 
 (P value <0.05) 
TGL (mg/dl) 235.82+or-105.18 155.81+or-61.08 
Significant difference 
  present 
 (P value <0.05) 
HDL (mg/dl) 46.24+or-8.03 49.21+or-9.93 
No significant difference
(P value >0.05) 
LDL (mg/dl) 125.82+or-41.66 111.45+or-27.80 
Significant difference 
  present 
 (P value <0.05) 
 ABSTRACT OF DATA: 
 
LIVER ENZYMES: 
ENZYME 
LEVEL(IU/L)/ 
TOTAL 
NAFLD 
GROUP(63) 
NORMAL 
USG(66) 
P VALUE 
SGOT < 25(96) 43 53 >0.05 
          >=25(33) 20 13  
SGPT < 25(89) 35 54 <0.05 
          >=25(40) 28 12  
ALP <=150 (90) 43 47 >0.05 
         > 150 (39) 20 19  
 
 
 
LIPID PROFILE 
PARAMETER(mg/dl)/ 
TOTAL 
NAFLD 
GROUP (63) 
NORMAL 
USG(66) 
P VALUE 
TC  <=200   (60) 19 41 <0.05 
         >200   (69) 44 25  
TGL <=150 (53) 15 38 <0.05 
         >150   (76) 48 28  
HDL < 50    (71) 40 31 >0.05 
         >=50   (58) 23 35  
LDL <=100  (43) 18 25 >0.05 
         >100    (86) 45 41  
 
 
Statistically Significant difference at 5% level (P=0.05) between NAFLD 
and NORMAL USG groups was present for SGPT, Total Cholesterol and 
Triglyceride levels. Other parameters did not show any significant difference 
by comparing the two groups using ‘chi square test’. But mean LDL levels in 
the NAFLD group were much higher than in that of the normal group. 
 
 
LIVER BIOPSY 
Liver biopsy was done only in 7 selected cases (10 % of cases with NAFLD on 
USG) for the confirmation of diagnosis and to get a bird’s eye view of the 
histological changes. Out of the 7 samples 1 patient had steatosis along with 
significant inflammatory cell infiltrate in the periportal regions with evidence of 
hepatocyte necrosis and feathery degeneration of hepatocytes signifying 
steatohepatitis. All the six others had steatosis only. No sample showed any 
evidence of cirrhosis or malignancy. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DISCUSSION 
A total of 129 patients were included in this study after applying the 
selection criteria, 
Out of the 129 type 2 diabetics included in this study 71 were females and 
59 were males, the number of males was lesser than females because alcohol 
intake was taken as exclusion criteria and so many males got excluded.  
of the 129 diabetics included in this study 63( 48 %) of them had 
ultrasonographically detectable fatty liver, according to several reports the 
prevalence of fatty liver in  Diabetes mellitus is more than that of the general 
population, many studies have shown that the prevalence of NAFLD in type 2 
Diabetes mellitus  was up to 70%.  
The study of fatty liver in type 2 Diabetes mellitus 
Series Prevalence of NAFLD by USG (%) 
Present ( n=129) 48.8% 
Daad H akbar (n=119)85 55% 
Gupte P et al (n = 100)108 49% 
Kelley D E et al (NA) 63% 
 
  The prevalence of fatty liver in this study group is similar to the prevalence 
observed in other studies.  
 
 
Out of the 70 female type 2 diabetics 41(58.6%) had fatty liver detected by 
ultrasonography and out of the 59 male type 2 diabetics 22 (37.29%) had fatty 
liver. In this study female sex had a higher prevalence of fatty liver (M: F ratio is 
1: 1.57). 
Many studies have shown that female sex has a higher predisposition to the 
development of fatty liver in the general population. In other studies conducted 
among type 2 diabetics the prevalence was found to be more among females2,5,6,9. 
 
There was no significant variation in the mean age between the NAFLD 
group and the normal liver group. The mean age of the study population was 
higher because only persons above the age of 40 years were recruited into the 
study. 
NAFLD has been described in different age groups, and even studies have 
been done in pediatric populations33, 37. 
 
DURATION OF DIABETES: 
The mean duration of Diabetes in persons with NAFLD was 5.47+ or – 
3.19    years and the mean duration of Diabetes in persons with Normal liver in 
USG was 5.47+ or – 3.94    years. 
No statistically significant relationship was found between the presence of 
NAFLD and the duration of Diabetes. The results are similar to the study 
conducted in Saudi Arabia (Daad H Akbar et al)85. 
BODY MASS INDEX: 
The mean Body Mass Index in the NAFLD group was significantly higher 
than that of the normal group. 41persons had a BMI of more than 25 kg/m2 and 
out of them 33 (80.48%) had NAFLD.   
In many studies Body Mass Index had a significant relationship with 
NAFLD, and Obesity had an association of 100 % with NAFLD in a few studies. 
In the study done by Daad H akbar et al in Saudi Arabia, Obesity was identified 
as an independent factor for the development of NAFLD85. 
The number of persons with a BMI of more than 30 kg/m2 was less compared to 
studies done in other countries. This is probably due to the low and middle 
socioeconomic status of the study group. In our study group too the persons with 
high BMI had prevalence of fatty liver equal to that observed else where. 
In one study it was said that Prevalence of NAFLD in patients with 
obesity or type 2 diabetes can be as high as 80-90% (Silverman et al, 198931, 
199019; Angelico et al, 200387), although large studies are not available. In 
one study, liver biopsy of people with diabetes, obesity or dyslipidaemia 
found an 82% prevalence of NASH (Marchenisi et al, 2004)88. 
 
 
 
CLINICAL SYMPTOMS: 
Following are the clinical symptoms observed in the group with NAFLD 
Compared to other studies: 
Symptoms and signs Present series       
 (n=63)
Virginia series86 
(n=75)
Saudi series85 
(n=64) 
asymptomatic 60% 60% 80% 
Fatigue 25% 30% NA 
Right upper 
quadrant discomfort 
22% 30% 17% 
Jaundice 0% NA NA 
One study had mentioned that approximately 25% of subjects with NAFLD 
also carry a diagnosis of chronic fatigue syndrome89.  
Our study group had a slight but statistically insignificant variation in the 
incidence of symptoms. 
The natural history of NASH in Australia was followed in 42 patients 
for up to 21 years 9. Upper abdominal pain was a common reason for 
presentation. Many studies have shown that A high proportion of patients 
(48% to 100%) have no symptoms of liver disease, and a small percentage 
(especially children 12,91) have vague abdominal discomfort or pain in the 
right upper quadrant 91,10 or fatigue and malaise 8,10 
 
 
HEPATOMEGALY: 
On clinical examination and Ultrasonogram wise 12 patients (19 %) out of 
63 with NAFLD group had hepatomegaly. The incidence of hepatomegaly in 
different studies in diabetics is as follows. 
Series No of patients (%) 
Lal et al (1971)93 10 out of 25 (38.5%) 
Vaishnava (1970)94 28 out of 113 (24.7%) 
Virginia series (1996)86 16 out of 75 (22%) 
Saudi series (2003)85 56 out of 64 (88%) 
Present series 12 out of 63 (19 %) 
 
There were gross variations in the incidence of hepatomegaly between 
many groups. 
None of the patients in the NAFLD group had splenomegaly or ascites. 
 
Many studies have shown that The most common finding at initial 
presentation is asymptomatic hepatomegaly 6,8,9,10 
 
 
 
 
 
 
LABORATORY INVESTIGATIONS: 
The prevalence of NAFLD was not significantly different among different levels 
of fasting sugar levels in our study. 
Many studies have shown that the levels of blood sugar did not have any 
correlation with development of NAFLD. More over HbA1c estimation was done 
in the Saudi study85, and there was no significant relationship between glycemic 
control and NAFLD. 
TRANSAMINASES AND ALKALINE PHOSPHATASE: 
There was no statistical difference between the two groups in terms of 
SGOT and Alkaline phosphatase elevation in terms of number of persons 
showing enzyme elevation. But when the mean enzyme values were compared 
the NAFLD group had a statistically significant higher value than the normal 
group. 
Asyptomatic elevation of transaminases is one of the commonest reported 
and studied abnormality in NAFLD. The most frequently noted abnormality is a 
two- to threefold elevation of levels of ALT and AST in plasma 6,8,9,10,12,13. Van 
Ness and Diehl 72 found that 19% of patients (17 of 90) who had had liver biopsy 
for evaluation of chronically elevated plasma levels of ALT and AST in contrast 
to 7% to 9% of all patients who had had liver biopsies for other reasons, had 
nonalcoholic steatosis or steatonecrosis2,90.  
Alkaline phosphatase levels are abnormal in fewer than half of patients, 8,10. 
Another article has stated that Liver transaminases may be normal, or only 
marginally elevated (Mofrad et al, 2003)92. There is poor correlation between 
biochemistry, ultrasonography and histology, and the entire histological spectrum 
of NAFLD can be seen in individuals with normal transaminase values (Mofrad 
et al, 2003)92. 
Some studies have mentioned that Liver enzyme levels in NAFLD patients 
fluctuate, normal values being present in up to 78% of patients at any one 
time.95,96 When levels are elevated, the increase is mild and often restricted to one 
or both of alanine aminotransferase (ALT) and aspartate aminotransferase (AST). 
The AST:ALT ratio is usually less than 1, although it may reverse in the presence 
of cirrhosis.97. 
In Type 2 Diabetics enzyme elevation was found in a total of 19% of cases 
in persons with NAFLD in the Saudi study. Our study too has results comparable 
to that study. 
The SGOT: SGPT ratio in the NAFLD group in this study was 0.86. 
In cases with NAFLD the SGOT: SGPT ratio is less than 1 according to 
literature. In two major studies 9,10, levels of ALT were noted to be higher than 
levels of AST, a pattern that contrasts with that seen in alcoholic hepatitis. 
Although values < 1 suggest NAFLD, a ratio of > or = 2 is strongly suggestive of 
alcoholic liver disease 
 
There was no statistically significant difference in the levels of bilurubin 
and total proteins between the two groups which were similar to the observations 
done elsewhere. 
 
FASTING LIPID PROFILE: 
Traditionally Total Cholesterol and Triglyceride values were found to be 
elevated in persons with NAFLD. Our study population consisted of type 2 
diabetics and atherogenic dyslipidemias are common among diabetics. 
The Total Cholesterol, TGL, values were significantly higher in terms of number 
of persons showing elevation and also in terms of the mean values in the NAFLD 
group. The number of persons showing elevated LDL was similar in both groups 
but the mean LDL was much higher in the NAFLD group. 
 Type of Lipid  % of persons  Mean value (mg/dl) 
Increased TC 69.8% 225.3 + or – 43.95 
Increased TGL 76.2% 235.82  +or – 105.18 
Increased LDL 60.6% 128.52 + or – 8.03 
Decreased HDL 71.4% 46.54 + or – 41.66 
 
The HDL values were similar in both groups with mean values being marginally 
lower in the NAFLD group. 
The values observed in other studies are as follows. Hyperlipidemia 
(hypertriglyceridemia, hypercholesterolemia, or both) is another common 
abnormality and has been reported in 20% to 81% of patients with NAFLD 
2,6,7,8,9,10,13. Dyslipidemia was present in 65% of the cases of NAFLD at the 
Virginia NAFLD clinic86. In another study, Hypertriglyceridemia and fatty liver: 
clinical diagnosis of fatty liver and lipoprotein profiles in hypertriglyceridemic 
patients with fatty liver, Most of the patients with fatty liver had 
hypertriglyceridemia. 
Our population too showed a positive correlation of NAFLD with elevated 
lipid levels. 
Ongoing research has now shown that Non alcoholic fatty liver disease has 
a broad clinical spectrum, different presentations, most of the research has shown 
that NAFLD has a stable course, some subsets of the NAFLD population might 
have a progression to severe forms of disease with inflammation termed 
steatohepatitis and a minority may end up in having cirrhosis. A significant 
proportion of patients previously thought to have cryptogenic cirrhosis share 
many of the clinical and demographic features of NAFLD, suggesting that the 
etiology of their cirrhosis may be unrecognized NAFLD (Powell et al, 19909; 
Cadwell et al, 199938; Poonawala et al, 200098). Outcomes of NAFLD are 
different among different groups and other studies that looked at the outcome of 
people with NAFLD and Diabetes also report a more aggressive form of disease 
and higher overall mortality and mortality related to liver disease (Sargin et al, 
2003). Older age, increasing obesity, type 2 Diabetes and hypertriglyceridaemia 
appear to be the strongest independent predictors of more advanced disease 
(Angulo et al, 199916; Dixon et al, 2001101). 
Follow up of patients with NAFLD has been discussed and monitoring 
patients with NAFLD is difficult because liver enzyme levels tend to improve 
regardless of whether liver fibrosis worsens or improves.102 In addition, it may 
take several decades of monitoring before the development of complications is 
observed. Therefore, follow-up should be focused on patients who have risk 
factors for advanced disease. 
 
 
 
 
 
 
LIMITATIONS OF THIS STUDY 
Although ultrasound was sensitive for the detection of steatosis its accuracy was 
greater if more than 30% of the liver was affected by steatosis. This might lead to 
an under-estimation of prevalence. But several studies have been conducted with 
Sonography alone and our study was based on those lines. 
 Since our study population was derived from the patients attending 
outpatient clinic, liver biopsy was not feasible in all cases because many patients 
were not willing for invasive procedures or inpatient stay. So only a 
representative sample from the fatty liver group had a liver biopsy done. As in all 
imaging procedures observer error is expected and we tried to minimize this error 
by review of images by another radiologist. 
 Moreover certain investigations like insulin levels, C- peptide levels, 
Hb A1c, Transferrin saturation and ferritin levels could not be done in our setup. 
So we were unable to document hyperinsulinemia etc. 
   
 
 
 
CONCLUSIONS 
1. Non alcoholic fatty liver disease is common among the type 2 diabetic 
population of this region.(  prevalence 48.8% of type 2 diabetics)  
2. Female sex has a significantly higher prevalence of non alcoholic fatty 
liver disease as observed in other geographical regions. (M: F ratio is 
1: 1.57). 
3. The persons with a higher body mass index are at a greater risk of 
developing non alcoholic fatty liver disease ( 80.49% diabetics with a 
BMI > 25 kg/m2 had ultrasonographically proven fatty liver) 
4. Most of the cases of non alcoholic fatty liver disease are 
asymptomatic. (60.32%). Right Upper Quadrant discomfort and 
malaise are other symptoms. 
5. Hepatomegaly was the commonest physical finding in Non alcoholic 
fatty liver disease (in19.04%). It was found to be present in varying 
incidences in other studies.  
6. No significant relationship was observed between the age of patient, 
duration of diabetes, fasting blood sugar levels and the presence of 
non alcoholic fatty liver disease by ultrasound. 
7. There was a significant difference in mean serum transaminase 
(SGOT, SGPT) levels between the normal and fatty liver groups with 
the fatty liver group having higher values. But absolute elevation of 
transaminases above normal was not seen in many cases. 
8. There was no significant relationship observed between serum 
alkaline phosphatase, total bilurubin, and total proteins and the 
presence of fatty liver by ultrasound. 
9. Significantly high Serum Total Cholesterol, Triglyceride and Low 
Density Lipoprotein Levels Were Present in Persons with Fatty Liver.    
10. No significant correlation was observed between low High Density 
Lipoprotein levels and the presence of fatty liver in ultrasound but 
marginally low mean High Density Lipoprotein values were present in 
the fatty liver group. 
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PROFORMA
NAME: AGE/SEX:
OCCUPATION: I.P / O.P NO:
ABDOMINAL DISTENSION OTHERS:
CLINICAL FINDINGS
HEPATOMEGALY SPLENOMEGALY
COMPLAINTS
Rt UPPER QUADRANT PAIN ABDOMINAL MASS JAUNDICE
H/O DRUG INTAKE
AMIODARONE VALPROATE a+ CHANNEL BLOCKER
OTHERS:
ALCOHOL INTAKE: YES NO 
HEIGHT (cm ): WEIGHT (kg ): BMI:
LIVER FUNCTION TESTS BLOOD SUGAR
ANTICANCER DRUGS GLITAZONES
OTHERS:
DURATION OF DIABETES:
Sr. LDL
Sr. HDL
SGOT  RANDOM
SGPT FASTING
Sr. TRIGLYCERIDES
LIVER BIOPSY:
Sr. ALK. PHOSPHATASE POST PRANDIAL
Sr. BILURUBIN ULTRASONOGRAM 
Sr. TOTAL PROTEINS
LIPID PROFILE
Sr.T. CHOLESTEROL
Sr. VLDL

CONCLUSIONS 
1. Non alcoholic fatty liver disease is common among the type 2 
diabetic population of this region.(  prevalence 48.8% of type 2 
diabetics)  
2. Female sex has a significantly higher prevalence of non alcoholic 
fatty liver disease as observed in other geographical regions. (M: F 
ratio is 1: 1.57). 
3. The persons with a higher body mass index are at a greater risk of 
developing non alcoholic fatty liver disease ( 80.49% diabetics with a 
BMI > 25 kg/m2 had ultrasonographically proven fatty liver) 
4. Most of the cases of non alcoholic fatty liver disease are 
asymptomatic. (60.32%). Right Upper Quadrant discomfort and 
malaise are other symptoms. 
5. Hepatomegaly was the commonest physical finding in Non alcoholic 
fatty liver disease (in19.04%). It was found to be present in varying 
incidences in other studies.  
6. No significant relationship was observed between the age of patient, 
duration of diabetes, fasting blood sugar levels and the presence of 
non alcoholic fatty liver disease by ultrasound. 
7. There was a significant difference in mean serum transaminase 
(SGOT, SGPT) levels between the normal and fatty liver groups with 
the fatty liver group having higher values. But absolute elevation of 
transaminases above normal was not seen in many cases. 
8. There was no significant relationship observed between serum 
alkaline phosphatase, total bilurubin, and total proteins and the 
presence of fatty liver by ultrasound. 
9. Significantly high Serum Total Cholesterol, Triglyceride and Low 
Density Lipoprotein Levels Were Present in Persons with Fatty Liver.    
10. No significant correlation was observed between low High Density 
Lipoprotein levels and the presence of fatty liver in ultrasound but 
marginally low mean High Density Lipoprotein values were present 
in the fatty liver group. 
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